The 46 references in paper О. Шахматова О. (2014) “ПРОБЛЕМА ВНУТРИЧЕРЕПНЫХ КРОВОИЗЛИЯНИЙ НА ФОНЕ ПРИЕМА «НОВЫХ» АНТИ КОАГУЛЯНТОВ” / spz:neicon:aterotromboz:y:2014:i:2:p:58-69

1
Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke, 1991, 22: 571–6.
(check this in PDF content)
2
Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke, 2005, 36(7): 1588–1593.
(check this in PDF content)
3
Flaherty ML, Kissela B, Woo D et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology, 2007, 68(2): 116–121.
(check this in PDF content)
4
Daniel M. Witt, Thomas Delatea, Elaine M. Hylekc et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thrombosis Research, 2013, 132: 770–775.
(check this in PDF content)
5
Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke, 2006, 37(1): 256–262.
(check this in PDF content)
6
Бойцов С.А., Якушин С.С., Марцевич С.Ю. и соавт. Амбулаторно-поликлинический регистр кардиоваскулярных заболеваний в Рязанской области (РЕКВАЗА): основные задачи, опыт создания и первые результаты. РФК, 2013, 9(1): 4-14.
(check this in PDF content)
7
Якушин С.С. Оптимальная медикаментозная терапия в клинике внутренних болезней: от клинических рекомендаций к реальной практике. Доклад на XIII Межрегиональной конференции РНМОТ. Режим доступа: http://www.rnmot.ru/public/ files/library/1/belgorod_2014_23.pdf.
(check this in PDF content)
8
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009, 361: 1139–51.
(check this in PDF content)
9
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al. Apixaban in patients with atrial fibrillation. N Engl J Med2011, 364: 806–17.
(check this in PDF content)
10
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011, 365: 883–91.
(check this in PDF content)
11
Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med2013, 369: 2093-2104.
(check this in PDF content)
12
Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the effi cacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet2014, 383: 955–962.
(check this in PDF content)
13
Sorensen R, Gislason G, Torp-Pedersen C et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJOpen 2013, 3: e002758. doi:10.1136/bmjopen-2013-002758.
(check this in PDF content)
14
Larsen TB, Rasmussen LH, Skjњth F et al. Efficacy and safety of dabigatran etexilate and warfarin in «realworld» patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol2013, 61: 2264-2273.
(check this in PDF content)
15
Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes2012, 5: 615–21.
(check this in PDF content)
16
Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013, 368: 1272–1274.
(check this in PDF content)
17
Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med1994, 154 (13): 1449–1457.
(check this in PDF content)
18
Hankey GJ. Intracranial Hemorrhage and Novel Anticoagulants for Atrial Fibrillation: What Have We Learned? Curr Cardiol Rep2014, 16: 480.
(check this in PDF content)
19
Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012, 43: 1511–7.
(check this in PDF content)
20
Minmin Ma, Atte Meretoja, Leonid Churilov et al. Warfarin-associated intracerebral hemorrhage: Volume, anticoagulation intensity and location. Journal of the Neurological Sciences 2013, 332: 75–79.
(check this in PDF content)
21
Hankey GJ, Stevens SR, Piccini JP, et al. Predictors of intracranial hemorrhage among anticoagulated patients with atrial fibrillation: insights from the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Stroke.2012, 43: A152.
(check this in PDF content)
22
Domingues-Montanari S, Hernandez-Guillamon M, Fernandez-Cadenas I et al. ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging2011, 32: 551, 13–551: 22.
(check this in PDF content)
23
Aguilar MI, Brott TG. Update in Intracerebral Hemorrhage. The Neurohospitalist, 2011, 1(3): 148-159.
(check this in PDF content)
24
El Ahmadieh TY, Aoun SG, Daou MR et al. New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery. Journal of Clinical Neuroscience 2013, 20: 1350–1356.
(check this in PDF content)
25
Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009, 108: 1447–52.
(check this in PDF content)
26
Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol2010, 9: 1157–63.
(check this in PDF content)
27
Lee KR, Colon GP, Betz AL et al. Edema from intracerebral hemorrhage: the role of thrombin. J Neurosurg1996, 84(1): 91–96.
(check this in PDF content)
28
Xi G, Reiser G, Keep RF. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J Neurochem 2003, 84(1): 3–9.
(check this in PDF content)
29
lvaro Cervera, Sergio Amaro, Angel Chamorro. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 2012, 259: 212–224.
(check this in PDF content)
30
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med2007, 120: 700–5.
(check this in PDF content)
31
Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010, 41: 2108–29.
(check this in PDF content)
32
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал, 2014, 4, 3.
(check this in PDF content)
33
Lip GH, Andreotti F, Fauchier L et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace 2011, 13 (5): 723-746.
(check this in PDF content)
34
Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost2011, 9: 1705–12.
(check this in PDF content)
35
Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood2013, 121: 3554–62.
(check this in PDF content)
36
Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Oral presentation number 17765 at 0930am on Monday November 18, 2013 at the American Heart Association Scientific Sessions (Room C140), Dallas, Texas, USA.
(check this in PDF content)
37
Lu G, DeGuzman FR, Hollenbach SJ, et al. Aspecific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. NatMed. 2013, 19: 446–51.
(check this in PDF content)
38
Crowther MA, Kitt M, McClure M, et al. Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors (abstract). Arterioscler Thromb Vasc Biol2013, 33: A10.
(check this in PDF content)
39
Crowther MA, Kitt M, Lorenz T, et al. A phase 2 randomized, doubleblind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors (abstract). J Thromb Haemost2013, 11: AS20.1.
(check this in PDF content)
40
Laulicht B, Bakhru S, Lee C, et al. Small molecule antidote for anticoagulants (abstract). Circulation2012, 126: 10021.
(check this in PDF content)
41
Laulicht B, Bakhru S, Jiang X, et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 (abstract). J Thromb Haemost 2013, 11: AS47.1.
(check this in PDF content)
42
Stollberger C, Finsterer J. Reservations against new oral anticoagulants after stroke and cerebral bleeding. Journal of the Neurological Sciences2013, 330: 16–17.
(check this in PDF content)
43
O’Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med2000, 342(4): 240–245.
(check this in PDF content)
44
Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke,2003, 34(7): 1710–1716.
(check this in PDF content)
45
Jauch EC, Saver JL, Adams HP Jr et al. Guidelines for the early management of patients with acute ischaemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013, 44: 870–947.
(check this in PDF content)
46
Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost, 2014, 111: 808–816.
(check this in PDF content)